REVIEW

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors

C J Hawkey¹, M J S Langman²

¹ Division of Gastroenterology, Queen’s Medical Centre, University Hospital Nottingham, Nottingham, UK
² Department of Medicine, Queen Elizabeth Hospital, Birmingham B12 2TH, UK

Correspondence to:
Correspondence to:
Professor C J Hawkey, Division of Gastroenterology, Queen’s Medical Centre, University Hospital Nottingham, Nottingham NG7 2UH, UK;
cj.hawkey{at}nottingham.ac.uk

Non-steroidal anti-inflammatory drugs (NSAIDs) are well recognised as causing peptic ulceration and ulcer complications. However, several critical issues, including the amount of both gastrointestinal and non-gastrointestinal disease affected by NSAIDs, their interaction with ancillary risk factors, and how to optimise management in subgroups, remain poorly understood. In this article, strategies for subgroups that take account of non-specific gastrointestinal risks, minimisation of residual risk, and the importance of non-gastrointestinal toxicity are suggested, and areas for research identified.

Keywords: non-steroidal anti-inflammatory drugs; ulcers; proton pump inhibitors; misoprostol; COX-2 inhibitors; aspirin; myocardial infarction

Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; COX, cyclooxygenase; PPI, proton pump inhibitor; NNT, number needed to treat

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Digest

Ian Forgacs
Gut 2003 52: 459. [Extract] [Full Text] [PDF]

Mucosal tears on endoscopic insufflation

K Hata, T Watanabe, T Kanazawa, S Kazama, D Shida, H Nagawa, and M Cruz-Correa
Gut 2003 52: 613. [Extract] [Full Text] [PDF]

Finding mucosal tears in collagenous colitis during colonoscopic insufflation

J C Yarze and M Cruz-Correa
Gut 2003 52: 613-614. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Dieppe, P. (2006). Complicity theory: an explanation for the ;coxib problem'?. JRSM 99: 273-274 [Full Text]  
• Hawkey, C J (2005). COX-2 chronology. Gut 54: 1509-1514 [Abstract] [Full Text]  
• Lohmander, L S, McKeith, D, Svensson, O, Malmenas, M, Bolin, L, Kalla, A, Genti, G, Szechinski, J, Ramos-Remus, C, for the STAR Multinational Study Group, (2005). A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64: 449-456 [Abstract] [Full Text]  
• (2005). Taking stock of coxibs. DTB 43: 1-6 [Abstract] [Full Text]  
• Whittle, B J R (2003). New dogmas or old?. Gut 52: 1379-1381 [Abstract] [Full Text]